Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aim: This study aimed to assess the validity and reliability of the Turkish version of the Breast Cancer Awareness Scale (BCAS-TR) for assessing breast cancer awareness among Turkish women.

Methods: The data of this methodological study were collected by face-to-face interview technique from 352 women over 18 years of age at a family health centre in Ankara, Türkiye. The BCAS-TR, adapted from the original 35-item scale, assessed knowledge, attitudes and behaviours related to breast cancer. Confirmatory factor analysis (CFA), content validity, convergent and discriminant validity, concurrent validity and reliability analysis were performed. Champion's Health Belief Model Scale was used for concurrent validity.

Results: CFA supported the five-factor structure of the original scale. All fit indices met the recommended criteria. The values of AVE of all factors ranged between 0.579 and 0.853. AVE values (> 0.5) and discriminant validity analysis supported convergent and discriminant validity. Significant positive correlations with the Champion's Health Belief Model Scale demonstrated concurrent validity. The Cronbach α of the total scale is 0.907 (subscales ranged between 0.752 and 0.907). The composite reliability values of the subscales ranged between 0.770 and 0.949.

Conclusions: The BCAS-TR is a valid and reliable tool for assessing breast cancer awareness in Turkish women. This scale can be used by researchers and healthcare professionals to develop targeted interventions and improve early detection and prevention of breast cancer in Türkiye.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijn.70046DOI Listing

Publication Analysis

Top Keywords

breast cancer
24
cancer awareness
16
validity reliability
12
discriminant validity
12
scale
8
awareness scale
8
validity
8
assessing breast
8
awareness turkish
8
convergent discriminant
8

Similar Publications

The International Center for the Study of Breast Cancer Subtypes (ICSBCS) has played a vital role in defining and overcoming many inequities that exist in breast cancer treatment and outcome on a global basis through capacity-building programs that improve the management of breast cancer patients across the African diaspora. ICSBCS activities also fill critical gaps in disparities research related to the genetics of ancestry. Over the past 20 years, ICSBCS teams have spearheaded landmark studies documenting the relevance of genetic African ancestry to breast cancer risk, while also improving the quality of care delivered to patients in diverse communities.

View Article and Find Full Text PDF

Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.

View Article and Find Full Text PDF